Microbot Medical Inc. Reports Q1 2025 Financial Results with $2.6 Million Net Loss

Microbot Medical Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $2.6 million, or $0.08 per share, compared to a net loss of $2.4 million, or $0.17 per share, in the same period of 2024. The company's total current assets surged to approximately $30.7 million as of March 31, 2025, up from $5.8 million at the end of 2024, primarily due to a significant increase in marketable securities, which rose to $27.2 million from $2.4 million. This increase reflects the capital raised through various financing activities, including the issuance of common stock and warrants.

In terms of operational performance, Microbot's research and development expenses increased to $1.5 million in Q1 2025 from $1.2 million in Q1 2024, driven by higher payroll and manufacturing costs associated with the development of its LIBERTY® Endovascular Robotic Surgical System. General and administrative expenses also rose to $1.6 million from $1.2 million, attributed to increased payroll, professional services, and travel expenses. The company recorded other income of $316,000 related to a legal settlement, which contributed positively to its financial results.

Strategically, Microbot has made significant advancements in its product development, particularly with the LIBERTY® system, which is designed for minimally invasive surgical procedures. The company has successfully completed multiple preclinical studies, achieving a 95% success rate in reaching predetermined vascular targets. Additionally, Microbot has submitted a 510(k) premarket notification to the FDA for the LIBERTY® system, anticipating marketing clearance in the second quarter of 2025. The company has also received ISO 13485:2016 certification for its quality management system, which is essential for compliance with EU medical device regulations.

As of March 31, 2025, Microbot's total liabilities decreased to $1.9 million from $2.5 million at the end of 2024, while shareholders' equity increased significantly to $29 million from $3.5 million, reflecting the successful capital raises. The company has raised approximately $105.5 million since its inception, with a cumulative loss of $93.5 million. Looking ahead, Microbot expects to continue incurring losses as it advances its research and development efforts and prepares for commercialization. The company plans to raise additional funds through future equity and debt securities to support its operations and product development initiatives.